+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Drugs Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cancer Type (Cholangiocarcinoma, Hepatoblastoma, Hepatocellular Carcinoma (HCC)), Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Liver Cancer Drugs Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cancer Type (Cholangiocarcinoma, Hepatoblastoma, Hepatocellular Carcinoma (HCC)), Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Liver Cancer Drugs Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cancer Type (Cholangiocarcinoma, Hepatoblastoma, Hepatocellular Carcinoma (HCC)), Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896742
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver cancer drugs market is experiencing a phase of rapid transformation, propelled by shifts in treatment paradigms and evolving industry dynamics. Senior decision-makers in pharmaceuticals must navigate complex supply chains, new regulatory environments, and the drive for patient-centricity to remain competitive in this growing segment.

Market Snapshot: Liver Cancer Drugs Market Outlook

The Liver Cancer Drugs Market grew from USD 987.60 million in 2024 to USD 1.12 billion in 2025. It is expected to continue growing at a CAGR of 14.08%, reaching USD 2.17 billion by 2030. This robust expansion reflects the industry’s strategic response to the rising global disease burden and increasing demand for targeted liver cancer therapeutics. Innovative drug classes, novel delivery approaches, and a move towards personalized care are shaping both market dynamics and long-term investment priorities across leading regions.

Scope & Segmentation: Coverage Across Key Liver Cancer Segments and Regions

This report delivers granular insight across the liver cancer drug value chain, assessing evolving technology, drug classes, and distribution models relevant to stakeholders. The scope includes:

  • Therapy Types: Covers chemotherapy, immunotherapy, radiation therapy, and targeted therapy, reflecting adoption of both established and next-generation treatments.
  • Cancer Types: Focuses on hepatocellular carcinoma (HCC), cholangiocarcinoma, and hepatoblastoma, each presenting distinct clinical profiles.
  • Administration Routes: Encompasses intravenous, oral, and subcutaneous approaches to enable adaptable care models and patient choice.
  • Drug Classes: Analyzes cytotoxic agents, monoclonal antibodies, and tyrosine kinase inhibitors (TKIs), highlighting the diversification of therapeutic portfolios.
  • End Users: Examines hospitals, specialty clinics, and home care to reflect the shift toward decentralized care and associated logistical needs.
  • Distribution Channels: Includes hospital, retail, and online pharmacies, addressing changes in patient access and drug delivery.
  • Regional Coverage: Offers detailed segmentation across the Americas (including US states such as California, Texas, New York, Florida), EMEA (UK, Germany, France, Middle East, Africa), and Asia-Pacific (China, India, Japan, Australia, and more).
  • Leading Companies: Profiles Bayer AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Ipsen S.A., AstraZeneca plc, and Exelixis, Inc., assessing strategic positioning and innovation priorities.

Liver Cancer Drugs Market: Key Takeaways for Leadership

  • Adoption of immunotherapies and targeted agents is outpacing traditional cytotoxic regimens, elevating long-term outcomes and fostering new patient segments.
  • The transition to oral and subcutaneous formulations is minimizing hospital stays and promoting flexible, patient-centric delivery models.
  • Biomarker-driven patient stratification and liquid biopsy advancements enable precision treatment selection and real-time therapy monitoring.
  • Regional differences in healthcare infrastructure, reimbursement, and regulatory frameworks demand tailored go-to-market and partnership strategies.
  • Collaboration between biotechs and pharma multinationals is accelerating development of combination therapies and supporting rapid portfolio expansion.
  • Digital health solutions, including remote monitoring and integrated platforms, are strengthening both patient engagement and clinical data collection.

Tariff Impact: Navigating Regulatory and Cost Dynamics

Recent US tariff policy updates have resulted in increased procurement costs and supply chain complexity for liver cancer drug manufacturers. These changes have emphasized the necessity of diversified sourcing, inventory buffers, and flexible supplier agreements. Forward-thinking companies are developing domestic supply partnerships and incorporating tariff harmonization clauses to maintain operational and financial stability while ensuring consistent therapeutic availability.

Methodology & Data Sources

This report synthesizes insights from peer-reviewed literature, regulatory briefings, clinical trial data, and patent analysis. Primary research involved interviews with oncology leaders, supply chain managers, and regulatory specialists, validated by anonymized patient data and real-world evidence analytics. Findings underwent expert panel review for relevance and accuracy, employing value chain and SWOT analysis to support decision making.

Why This Report Matters

  • Enables executive-level decisions by providing actionable intelligence on drug innovation, competitive positioning, and upcoming clinical advances.
  • Supports strategic investment by mapping evolving care models, distribution networks, and tariff-influenced procurement strategies.
  • Highlights real-world trends in market entry, regional dynamics, and stakeholder collaboration to strengthen leadership foresight and planning.

Conclusion

Innovation, strategic partnerships, and a focus on patient outcomes will define future success in the liver cancer drugs market. Decision-makers leveraging this analysis can position their organizations for growth and sustainable competitive advantage in this evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of immune checkpoint inhibitor combinations for advanced hepatocellular carcinoma treatment
5.2. Integration of biomarker-driven precision therapies based on genetic profiling in liver cancer management
5.3. Expansion of transarterial radioembolization coupled with systemic therapies in intermediate stage HCC
5.4. Development of next generation CAR T and T cell receptor therapies targeting liver cancer antigens
5.5. Growing emphasis on real-world evidence and digital health monitoring in hepatocellular carcinoma care
5.6. Market access challenges and pricing strategies for novel multi kinase inhibitors in liver cancer therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Liver Cancer Drugs Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Radiation Therapy
8.5. Targeted Therapy
9. Liver Cancer Drugs Market, by Cancer Type
9.1. Introduction
9.2. Cholangiocarcinoma
9.3. Hepatoblastoma
9.4. Hepatocellular Carcinoma (HCC)
10. Liver Cancer Drugs Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Liver Cancer Drugs Market, by Drug Class
11.1. Introduction
11.2. Cytotoxic Agents
11.3. Monoclonal Antibodies
11.4. Tyrosine Kinase Inhibitors (TKIs)
12. Liver Cancer Drugs Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospital
12.4. Specialty Clinic
13. Liver Cancer Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Americas Liver Cancer Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Liver Cancer Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Liver Cancer Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bayer AG
17.3.2. Eisai Co., Ltd.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Merck & Co., Inc.
17.3.5. F. Hoffmann-La Roche Ltd
17.3.6. Ipsen S.A.
17.3.7. AstraZeneca plc
17.3.8. Exelixis, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. LIVER CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. LIVER CANCER DRUGS MARKET: RESEARCHAI
FIGURE 28. LIVER CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. LIVER CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. LIVER CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 89. CANADA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 90. CANADA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 91. CANADA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 92. CANADA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 93. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 94. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 95. CANADA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 101. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 162. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 163. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 165. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 174. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 175. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 177. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 180. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 181. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. ITALY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 198. ITALY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 199. ITALY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 200. ITALY LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 201. ITALY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 202. ITALY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 203. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. ITALY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 210. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 211. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 213. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 258. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 259. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 261. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. QATAR LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 282. QATAR LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 283. QATAR LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 284. QATAR LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 285. QATAR LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 286. QATAR LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 287. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 288. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 289. QATAR LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. QATAR LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 294. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 295. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 296. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 297. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 298. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 299. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 330. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 331. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 332. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 333. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 334. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 335. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 336. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 337. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 342. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 202

Samples

Loading
LOADING...

Companies Mentioned

  • Bayer AG
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Ipsen S.A.
  • AstraZeneca plc
  • Exelixis, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.17 Billion
Compound Annual Growth Rate14.0%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Drugs - Global Strategic Business Report - Product Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030 - Product Image

Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030

  • Report
  • 100 Pages
  • Global
From
Liver Cancer Drug Global Market Report 2025 - Product Image

Liver Cancer Drug Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Liver Cancer Drugs Market 2025-2029 - Product Image

Liver Cancer Drugs Market 2025-2029

  • Report
  • 236 Pages
  • Global
From

About the Liver Cancer Drugs Market

The Liver Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat liver cancer. These drugs are used to reduce the size of tumors, reduce symptoms, and improve the quality of life for those affected by the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells. Immunotherapy is a type of drug that works by stimulating the body's own immune system to fight cancer. The Liver Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly developing new drugs and treatments to improve the quality of life for those affected by liver cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.